Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 388

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

Open access
Camidge, D. Ross, Kim, Hye Ryun, Ahn, Myung-Ju, Yang, James C.H., Han, Ji-Youn, Hochmair, Maximilian J., Lee, Ki Hyeong, Delmonte, Angelo, Garcia Campelo, Maria Rosario, Kim, Dong-Wan, Griesinger, Frank, Felip, Enriqueta, Califano, Raffaele, Spira, Alexander I., Gettinger, Scott N., Tiseo, Marcello, Lin, Huamao M., Liu, Yuyin, Vranceanu, Florin, Niu, Huifeng, Zhang, Pingkuan, Popat, Sanjay·2021·Journal of Thoracic Oncology

Abstract

INTRODUCTION: In the phase 3 study entitled ALK in Lung cancer Trial of brigAtinib in 1st Line (ALTA-1L), which is a study of brigatinib in ALK inhibitor-naive advanced ALK-positive NSCLC, brigatinib exhibited superior progression-free survival (PFS) versus crizotinib in the two planned interim analyses. Here, we report the final efficacy, safety, and exploratory results. METHODS: Patients were randomized to brigatinib 180 mg once daily (7-d lead-in at 90 mg once daily) or crizotinib 250 mg twice daily. The primary end point was a blinded independent review committee-assessed PFS. Genetic alterations in plasma cell-free DNA were assessed in relation to clinical efficacy. RESULTS: A total of 275 patients were enrolled (brigatinib, n = 137; crizotinib, n = 138). At study end, (brigatinib median follow-up = 40.4 mo), the 3-year PFS by blinded independent review committee was 43% (brigatinib) versus 19% (crizotinib; median = 24.0 versus 11.1 mo, hazard ratio [HR] = 0.48, 95% confidence interval [CI]: 0.35-0.66). The median overall survival was not reached in either group (HR = 0.81, 95% CI: 0.53-1.22). Posthoc analyses suggested an overall survival benefit for brigatinib in patients with baseline brain metastases (HR = 0.43, 95% CI: 0.21-0.89). Detectable baseline EML4-ALK fusion variant 3 and TP53 mutation in plasma were associated with poor PFS. Brigatinib exhibited superior efficacy compared with crizotinib regardless of EML4-ALK variant and TP53 mutation. Emerging secondary ALK mutations were rare in patients progressing on brigatinib. No new safety signals were observed. CONCLUSIONS: In the ALTA-1L final analysis, with longer follow-up, brigatinib continued to exhibit superior efficacy and tolerability versus crizotinib in patients with or without poor prognostic biomarkers. The suggested survival benefit with brigatinib in patients with brain metastases warrants future study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2021.07.035

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 388

Metadata

Authors
Camidge, D. R., Kim, H. R., Ahn, M.-J., Yang, J. C. H., Han, J.-Y., Hochmair, M. J., Lee, K. H., Delmonte, A., Garcia Campelo, M. R., Kim, D.-W., Griesinger, F., Felip, E., Califano, R., Spira, A. I., Gettinger, S. N., Tiseo, M., Lin, H. M., Liu, Y., Vranceanu, F., Niu, H., Zhang, P., & Popat, S.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2021-12
Volume
16
Issue
12
Pages
2091-2108
ISSN
1556-0864 (ISSN-L)
OpenAlex
W3200994971
Cited by
388
References
21
FWCI
34.33
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. https://app.cochat.ai/papers/10.1016/j.jtho.2021.07.035
The paper
Camidge, D. R., Kim, H. R., Ahn, M.-J., Yang, J. C. H., Han, J.-Y., Hochmair, M. J., Lee, K. H., Delmonte, A., Garcia Campelo, M. R., Kim, D.-W., Griesinger, F., Felip, E., Califano, R., Spira, A. I., Gettinger, S. N., Tiseo, M., Lin, H. M., Liu, Y., Vranceanu, F., . . . Popat, S. (2021). Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2021.07.035

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.